MONOMERIC Fc-FUSION PROTEINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 117

75. Meachem SJ, McLachlan RI, de Kretser DM, Robertson DM,
Wreford NG. (1996) Neonatal exposure of rats to recombi-
nant follicle stimulating hormone increases adult Sertoli and
spermatogenic cell numbers. Biol. Reprod. 54, 36-44.
76. Morris B, Morris R. (1974) The effects of cortisone acetate on
stomach evacuation and the absorption of 125 I-labelled glob-
ulins in young rats. J. Physiol. 240, 79-89.
77. Simister NE, Rees AR. (1985) Isolation and characterization
of an Fc receptor from neonatal rat small intestine. Eur. J.
Immunol. 15, 733-738.
78. Gillies S, Lan Y, Brunkhorst B, Wong W-K, Li Y, Lo K-M.
(2002) Bi-functional cytokine fusion proteins for gene ther-
apy and antibody-targeted treatment of cancer. Cancer Immu-
nol. Immunother. 51, 449-460.
79. Economides A, Carpenter L, Rudge J, Wong V, Koehler-Stec
E, Hartnett C, et al. (2003) Cytokine traps: multi-component,
high-affinity blockers of cytokine action. Nat. Med. 9, 47-52.
80. Cox GN, Smith DJ, Carlson SJ, Bendele AM, Chlipala EA,
Doherty DH. (2004) Enhanced circulating half-life and hem-
atopoietic properties of a human granulocyte colony-stimu-
lating factor/immunoglobulin fusion protein. Exp. Hematol.
32, 441-449.
81. Jazayeri JA, Carroll GJ. (2008) Fc-based cytokines: prospects
for engineering superior therapeutics. BioDrugs 22, 11-26.
82. Wang Q, Chen K, Liu R, Zhao F, Gupta S, Zhang N, et al.
(2010) Novel GLP-1 fusion chimera as potent long acting
GLP-1 receptor agonist. PLoS ONE 5, e12734.
83. Goldzweig O, Hashkes PJ. (2011) Abatacept in the treatment
of polyarticular JIA development clinical utility and place in
therapy. Drug Des. Devel. Ther. 5, 61-70.
84. Gottlieb AB. (2005) Alefacept for psoriasis and psoriatic
arthritis. Ann. Rheum. Dis. 64, iv58-iv60.
85. Molineux G. (2011) The development of romiplostim for
patients with immune thrombocytopenia. Ann. N.Y. Acad. Sci.
1222, 55-63.
86. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA,
Fleischmann RM, Weaver AL, et al. (1997) Treatment of
rheumatoid arthritis with a recombinant human tumor necro-
sis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med.
337, 141-147.
87. Stahl N, Radin A, Mellis S. (2009) Rilonacept—CAPS and
beyond. Ann. N.Y. Acad. Sci. 1182, 124-134.
88. Su VCh, Harrison J, Rogers C, Ensom MH. (2012) Belata-
cept: a new biologic and its role in kidney transplantation.
Ann. Pharmacother. 46(1), 57-67.

89. Ohr M, Kaiser PK. (2012) Intravitreal aflibercept injection for
neovascular (wet) age-related macular degeneration. Expert
Opin. Pharmacother. 13(4), 585-591.
90. Dwyer MA, Huang AJ, Pan CQ, Lazarus RA. (1999) Expres-
sion and characterization of a DNase I-Fc fusion enzyme.
J. Biol. Chem. 274, 9738-9743.
91. Lee CH, Woo JH, Cho KK, Kang SH, Kang SK, Choi YJ.
(2007) Expression and characterization of human growth
hormone-Fc fusion proteins for transcytosis induction. Bio-
technol. Appl. Biochem. 46, 211-217.
92. Hapuarachchi S, Fodor S, Apostol I, Huang G. (2011)
Use of capillary electrophoresis-sodium dodecyl sulfate
to monitor disulfide scrambled forms of an Fc fusion
protein during purification process. Anal. Biochem. 414,
187-195.
93. Sahdev S, Khattar S, Saini K. (2008) Production of active
eukaryotic proteins through bacterial expression systems: a
review of the existing biotechnology strategies. Mol. Cell.
Biochem. 307, 249-264.
94. De Pourcq K, De Schutter K, Callewaert N. (2010) Engi-
neering of glycosylation in yeast and other fungi: current
state and perspectives. Appl. Microbiol. Biotechnol. 87,
1617-1631.
95. Jacobs PP, Geysens S, Vervecken W, Contreras R, Callewaert
N. (2008) Engineering complex-type N-glycosylation in
Pichia pastoris using GlycoSwitch technology. Nat. Protoc.
4, 58-70.
96. Ghetie V, Ward ES. (2000) Multiple roles for the major
histocompatibility complex class I related receptor FcRn.
Annu. Rev. Immunol. 18, 739-766.
97. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal

Fc receptor comes of age. Nat. Rev. Immunol. 7,

715-725.
98. Ober RJ, Radu CG, Ghetie V, Ward ES. (2001) Differences in
promiscuity for antibody-FcRn interactions across species:
implications for therapeutic antibodies. Int. Immunol. 13,
1551-1559.
99. McCue JT, Selvitelli K, Walker J. (2009) Application of a
novel affinity adsorbent for the capture and purification of
recombinant factor VIII compounds. J. Chromatogr. A 1216,
7824-7830.
100. Zhang J, Carter J, Siu S, O'Neill JW, Gates AH, Delaney J,
et al. (2010) Fusion partners as a tool for the expression
of difficult proteins in mammalian cells. Curr. Pharm.
Biotechnol. 11, 241-245.